DrugCite
Search

MARAVIROC

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Maraviroc Adverse Events Reported to the FDA Over Time

How are Maraviroc adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Maraviroc, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Maraviroc is flagged as the suspect drug causing the adverse event.

Most Common Maraviroc Adverse Events Reported to the FDA

What are the most common Maraviroc adverse events reported to the FDA?

Myocardial Infarction
65 (2.58%)
Nausea
54 (2.14%)
Death
38 (1.51%)
Pyrexia
37 (1.47%)
Anaemia
33 (1.31%)
Stevens-johnson Syndrome
32 (1.27%)
Weight Decreased
31 (1.23%)
Diarrhoea
29 (1.15%)
Renal Failure
29 (1.15%)
Squamous Cell Carcinoma
29 (1.15%)
Thrombocytopenia
29 (1.15%)
Show More Show More
Abdominal Pain
27 (1.07%)
Viral Load Increased
26 (1.03%)
Acute Myocardial Infarction
25 (.99%)
Blood Creatine Phosphokinase Increa...
25 (.99%)
Vomiting
23 (.91%)
Chest Pain
22 (.87%)
Hypoxia
22 (.87%)
Cytolytic Hepatitis
21 (.83%)
Lymphoma
21 (.83%)
Headache
20 (.79%)
Pneumonia
20 (.79%)
Abdominal Distension
19 (.75%)
Sepsis
19 (.75%)
Drug Interaction
18 (.71%)
Hepatic Failure
18 (.71%)
Rectal Cancer
18 (.71%)
Lung Disorder
17 (.67%)
Neutropenia
17 (.67%)
Pulmonary Embolism
17 (.67%)
Anal Cancer
16 (.63%)
Immune Reconstitution Syndrome
16 (.63%)
Renal Failure Acute
16 (.63%)
Colon Cancer
15 (.59%)
Dyspnoea
15 (.59%)
Hyperlipidaemia
15 (.59%)
Intestinal Perforation
15 (.59%)
Pancreatitis
15 (.59%)
Pancytopenia
14 (.56%)
Polyarthritis
14 (.56%)
Proteinuria
14 (.56%)
Asthenia
13 (.52%)
Hyperglycaemia
12 (.48%)
Neuropathic Ulcer
12 (.48%)
Oedema Peripheral
12 (.48%)
Pruritus
12 (.48%)
Septic Shock
12 (.48%)
Vision Blurred
12 (.48%)
Acute Coronary Syndrome
11 (.44%)
Bacteraemia
11 (.44%)
Deep Vein Thrombosis
11 (.44%)
Gamma-glutamyltransferase Increased
11 (.44%)
Hypokalaemia
11 (.44%)
Metabolic Acidosis
11 (.44%)
Urinary Tract Infection
11 (.44%)
Angina Unstable
10 (.4%)
Cerebellar Ataxia
10 (.4%)
Epistaxis
10 (.4%)
Guillain-barre Syndrome
10 (.4%)
Paraesthesia
10 (.4%)
Alanine Aminotransferase Increased
9 (.36%)
Cardiac Arrest
9 (.36%)
Drug Toxicity
9 (.36%)
Erysipelas
9 (.36%)
Grand Mal Convulsion
9 (.36%)
Lung Neoplasm
9 (.36%)
Multiple Myeloma
9 (.36%)
Myalgia
9 (.36%)
Oesophageal Candidiasis
9 (.36%)
Type 2 Diabetes Mellitus
9 (.36%)
Aids Dementia Complex
8 (.32%)
Amnesia
8 (.32%)
Aspartate Aminotransferase Increase...
8 (.32%)
Bladder Neoplasm
8 (.32%)
Bradycardia
8 (.32%)
Dehydration
8 (.32%)
Dementia
8 (.32%)
Encephalitis Viral
8 (.32%)
Flatulence
8 (.32%)
Ileitis
8 (.32%)
Pain In Extremity
8 (.32%)
Psoriasis
8 (.32%)
Vulval Cancer
8 (.32%)
Blood Amylase Increased
7 (.28%)
Blood Creatinine Increased
7 (.28%)
Breast Calcifications
7 (.28%)
Breast Cancer
7 (.28%)
Demyelination
7 (.28%)
Dizziness
7 (.28%)
Fall
7 (.28%)
Gait Disturbance
7 (.28%)
Gastric Cancer
7 (.28%)
Injection Site Erythema
7 (.28%)
Lipodystrophy Acquired
7 (.28%)
Osteonecrosis
7 (.28%)
Phlebitis
7 (.28%)
Basal Cell Carcinoma
6 (.24%)
Blood Alkaline Phosphatase Increase...
6 (.24%)
Blood Potassium Decreased
6 (.24%)
Cardiac Failure
6 (.24%)
Cholecystitis
6 (.24%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Maraviroc, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Maraviroc is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Maraviroc

What are the most common Maraviroc adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Maraviroc, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Maraviroc is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Maraviroc According to Those Reporting Adverse Events

Why are people taking Maraviroc, according to those reporting adverse events to the FDA?

Hiv Infection
973
Hiv Test Positive
102
Product Used For Unknown Indication
18
Drug Use For Unknown Indication
10
Acquired Immunodeficiency Syndrome
8
Antiretroviral Therapy
7
Show More Show More
Hiv Tropism Test
6
Hiv Infection Cdc Group I
3
Hiv Infection Cdc Category C3
2
Hiv Test
2
Aids Encephalopathy
1
Retroviral Infection
1
Antiviral Treatment
1
Multiple-drug Resistance
1
Cd4 Lymphocytes Increased
1
T-lymphocyte Count Increased
1
Mental Disorder
1

Drug Labels

LabelLabelerEffective
SelzentryPfizer Laboratories Div Pfizer Inc27-MAY-10
SelzentryViiV Healthcare Company22-JUL-11
SelzentryPhysicians Total Care, Inc.23-MAY-12
SelzentryViiV Healthcare Company14-FEB-13
SelzentryREMEDYREPACK INC. 18-FEB-13

Maraviroc Case Reports

What Maraviroc safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Maraviroc. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Maraviroc.